title: Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.
abstract: To investigate the physiological role of atrial natriuretic factor (ANF) in patients with hypoxic pulmonary hypertension secondary to chronic obstructive lung disease (COLD), we infused synthetic alpha-human ANF in seven such patients, and investigated the physiological correlates to circulating peptide levels in 24 patients with COLD. ANF infusion, at incremental rates of 0.01, 0.03, and 0.1 micrograms/kg.min, increased basal plasma immunoreactive (ir) ANF (136 +/- 38 pg/ml) by 3-, 10-, and 26-fold, respectively, and reduced pulmonary artery pressure (from 33 +/- 3 to 25 +/- 2 mmHg, P less than 0.001) and systemic arterial pressure (from 88 +/- 4 to 79 +/- 4 mmHg, P less than 0.001) in a dose-related fashion. Cardiac index increased by 13.5% (P less than 0.01) while heart rate was unchanged. Cardiac filling pressures decreased at 0.1 micrograms/kg.min ANF. Pulmonary and systemic vascular resistance fell by 37% (P less than 0.001) and 19% (P less than 0.001), respectively. Arterial oxygenation was impaired during ANF infusion, suggesting partial reversal of hypoxic pulmonary vasoconstriction. Plasma renin activity remained unchanged but aldosterone fell by 44% (P less than 0.01). The levels of plasma irANF in 24 patients correlated directly with the degree of hemoconcentration (r = 0.67, P less than 0.001), respiratory acidosis (r = -0.65, P less than 0.001), and pulmonary hypertension (r = 0.52, P less than 0.01). The results suggest that ANF may serve as a potent pulmonary vasodilator involved in the circulatory homeostasis of patients with COLD.
authors.affiliation: Département de Physiologie, Hôpital Henri Mondor, Creteil, France.
authors.forename: S
authors.initials: S
authors.lastname: Adnot
authors.forename: P
authors.initials: P
authors.lastname: Andrivet
authors.forename: P E
authors.initials: PE
authors.lastname: Chabrier
authors.forename: J
authors.initials: J
authors.lastname: Piquet
authors.forename: P
authors.initials: P
authors.lastname: Plas
authors.forename: P
authors.initials: P
authors.lastname: Braquet
authors.forename: F
authors.initials: F
authors.lastname: Roudot-Thoraval
authors.forename: C
authors.initials: C
authors.lastname: Brun-Buisson
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000494:pharmacology / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006706:Homeostasis; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology*; D007700:Kinetics; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery / Q000503:physiopathology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012083:Renin / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation
chemical_list: D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin